Research

Bodour Salhia, Ph.D.

Dr. Salhia is a translational genomics scientist with extensive knowledge and expertise in mechanisms that underlie tumorigenesis and tumor biology. She merges cutting edge genomics/epigenomics analyses with cell biological and functional studies towards the investigation of clinically relevant problems in human cancer. During her graduate training, she focused on understanding the molecular and cellular determinants of glioma invasion. Her post-doctoral work focused on the genomics and epigenomics of breast cancer metastasis and multiple myeloma. She also characterized the function of AKT1(E17K) in breast cancer and performed immunophenotypic analysis of breast cancer in North Africa. She has led and continues to lead numerous DNA methylation studies using a plethora of both array and sequencing based technologies to measure whole genome and targeted CpG methylation changes in a variety of cancer types. Dr. Salhia utilizes these data to develop DNA methylation liquid biopsies. Her lab is in the process of validating a DNA methylation liquid biopsy for breast cancer recurrence which would indicate patients with evidence of micrometastatic residual disease that are therefore likely to experience a recurrence. Dr. Salhia’s lab also has research efforts in experimental therapeutics of brain metastasis by utilizing patient-derived xenografts and cell lines to identify novel treatment methods for this dismal disease.

Brooke Hjelm, Ph.D.

Dr. Hjelm’s research focuses on two separate yet complimentary areas: (1) the utilization of next generation genomic, transcriptomic, and proteomic technologies to profile recurrent and/or refractory pediatric, adolescent, and young adult (AYA) cancer patients for clinical decision making; (2) the use of functional genomics to identify and interrogate the developmental and therapeutic aspects of sarcomas that predominantly arise in the pediatric and AYA populations. Her overall research interests are a reflection of my diverse training history. She has interest in rhabdomyosarcomas (RMS), desmoplastic small round cell tumors (DSRCT), Ewing sarcomas (EWS), and clear cell sarcomas (CCS). The relatively low mutation burden in numerous different types of sarcomas suggests that there are transcriptional and/or epigenetic mechanisms that drive these diseases. This is inline with recent studies suggesting that epigenetic dysregulation and altered developmental programing drive many pediatric malignancies. Moreover, the mechanisms by which sarcoma-specific oncogenic fusion genes initiate and/or sustain disease remains elusive. Her laboratory is dedicated to developing new biological tools and approaches to enable a functional genomics inquiry into these mechanisms as to reveal insight into the underlying biology of these sarcomas. Additionally, her lab interrogates patient derived material to better define the molecular characteristics of different sarcoma subtypes to enable more precise treatment strategies for these difficult diseases.

Zarko Manojlovic, Ph.D.

Dr. Manojlovic in an Assistant Professor in the department of Translational Genomics and the Director of the newly formed Keck Genomics Platform (KGP) at the Keck School of Medicine of University of Southern California.In his role as an Assistant Professor, Dr. Manojlovic has a continued interest in urothelial carcinomas, with a focus on utilizing next generation sequencing and “omics” to elucidate population and tumor heterogeneity, as well as tumor microenvironments at the nexus of informatics and functional biologics with direct clinical implications. Dr. Manojlovic plans to expand profiling and comprehensive molecular analysis of the organ-confined elusive low-grade heterogeneous urothelial carcinomas that escape standard treatments and escalate into aggressive high-risk tumors with a high rate of mortality. Furthermore, building on his previous experiences with continuous collaborations, Dr. Manojlovic is interested in interrogating the ancestral effects on disease progression and outcomes in the urothelial tumors. His group provides opportunities in dual training in functional bioinformatics, with emphasis on clinical biologics approaches. Dr. Manojlovic has a major focus on applications of high throughput genomics critical to elucidate the oncogenic transcriptomes and genomes to identify clinically targetable events under the umbrella of precision medicine. To learn more about ongoing activities in his group, please see his Laboratory Page.

Enrique Velazquez, M.D., Ph.D., M.P.H

Dr. Velazquez’s research involves two main components. First it integrates clinical and genomic data that is pulled from multiple sources, e.g. Electronic Health Records (EHR), by using big data management systems and big data analytic techniques. Second, it uses gene expression to discover genomic level biomarkers related to cognitive function in individuals with neurological disease. As a teacher, he leads classes in statistics, data analytics, and bioinformatics, and as a bench scientist, he has studied neurological conditions, transplantation immunology, and basic cell biology and mechanisms. As an epidemiologist, he’s committed to delivering precision public health, using genetic data to assess risk and inform prevention strategies for individuals and communities. As a native of Mexico, he is part of USC’s Translational Genomic’s efforts to build and learn from diverse populations in order to serve diverse populations. To learn more about ongoing activities in his group, please see his Laboratory Page.